1 / 17

Lupin Press Meet

Lupin Press Meet. October 7, 2003. Background and Origin. Current Operations and Strengths. Recent Business Successes. Strategy for the Future. The Building Blocks. Glimpse into the Future. Background and Origin. Background and Origin.

avak
Download Presentation

Lupin Press Meet

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lupin Press Meet October 7, 2003

  2. Background and Origin Current Operations and Strengths Recent Business Successes Strategy for the Future The Building Blocks Glimpse into the Future

  3. Background and Origin

  4. Background and Origin • Started in 1968 by the Founder Chairman Dr Desh Bandhu Gupta in Mumbai • Now spread over 6 locations in India and a location in Thailand • Represented through Sales offices in UK, USA, Hong Kong, Japan and CIS • Widely held and listed on all major Stock Exchanges • 3300 employees

  5. Current Operations and Strengths

  6. Current Operations • Among the top 6 Pharma companies in India • Turnover of Rs 1120 Cr and PBT of Rs 97 Cr • Integrated player with significant presence in both API and Formulations • API Sales spread over more than 50 countries globally • Strong Formulation Sales across India • 1/3rd of Revenues from Exports

  7. Performance at a glance CAGR 11% CAGR 22%

  8. Segment Trends • Formulations in India grew at 19 % in Q1 ( FY 03-04) outperforming the market growth of 6 % as per ORG. This segment will continue to be a growth driver. • Exports surged by 41 % and is expected to be the leading growth driver in the future. • Regulated markets contribution to the company topline stands at 31 % and is likely to grow further.

  9. Strengths • Increasing Presence in the Advanced markets of US and Europe • 9 out of 10 Plants are US FDA approved • Strong Integrated R&D program encompassing NCE, NDDS and Process Research • World Leader in Anti TB • Strong Position in Cephalosporins and Cardiovasculars

  10. Recent Business Successes

  11. Recent Business Successes • Consolidation of our Presence in Advanced Nations • 5 ANDAs filed and 3 approved • 12 DMFs filed • First Generic formulation (Cefuroxime Axetil) launched in US • 110 patents filed and 50 granted • Ceff-ER, world’s first once a day Cephalexin developed and launched • 8 Brands in India’s top 300

  12. Strategy for the Future

  13. Strategy for the Future • Advanced Generic Mkts • Expand APIs by partnering with niche players • Grow formulations through Alliances • Direct marketing of Branded formulations • API and Intermediates - In Domestic and Developing markets by emphasizing on Cost leadership and long term supply contracts • Formulations – In Domestic and Select Developing markets through consolidating the Acute therapy segments and building Chronic lifestyle segments

  14. The Building Blocks

  15. Building Blocks • Professionalization of Mgmt by inducting top notch senior professionals • State of art IT initiative in place • Strong QA program in place • Focus on expanding capacity • Leveraging R&D strengths for Business • Comprehensive Process for Intellectual Property Management • Two World class Investors being inducted • Financial Restructuring • Slew of HR initiatives • Linkages with Strategy and Operations • Enhancing the Leadership pool • Very high degree of focus on Corporate Governance

  16. Glimpse into the Future

  17. Lupin of the Future • Be among top 3 pharma companies in India • Majority of Revenues from the Advanced markets • To have Higher and Sustainable earnings • R&D program to contribute significantly to the Bottomline • Moving the Business Model up the Value Chain by enhancing the Product and Geography Mix • To be known as a Venerable Institution rather than a mere Organization • Maximizing Value for all Stakeholders

More Related